

Radboud University Medical Center,
Nijmegen, The Netherlands

D. Maroeska te Loo

Pediatric Hemato-Oncology, Department of Pediatrics,
Radboud University Medical Center,
Nijmegen, The Netherlands

F.N.v.L. and D.M.t.L. contributed equally to this study.

The online version of this article contains a data supplement.

Acknowledgments: The authors thank Dr Jeroen Middelbeek for help with microscopy imaging and Simon van Reijmersdal for technical assistance. This work was supported in part by research funding from KiKa (grant #134) (L.T.v.d.M.).

Contribution: L.T.v.d.M. performed experiments, analyzed and interpreted data, and wrote the manuscript; E.W. designed and performed the genomic analysis; M.L. performed research; H.V. performed in silico structure analysis; D.R. performed research; J.B. and C.L. performed drug monitoring and designed research; R.J.B. performed the pharmacokinetic studies; R.P.K. analyzed and interpreted the genomic analysis; P.H. designed the research and interpreted the data; F.N.v.L. and D.M.t.L. designed and supervised the research; and all authors edited and approved the manuscript.

Conflict-of-interest disclosure: J.B. served personally as a consultant and participated in advisory boards and safety boards for different asparaginase-selling companies including EUSA Pharma and former Erwinase license holders, Bayer and Medac GmbH. The laboratory at the University of Münster is also involved in scientific collaborations with EUSA, Medac, and Sigma-Tau, which to some extent contributed financially to the analytical procedures. The remaining authors declare no competing financial interests.

Current affiliation for D.R. is Department of Experimental Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands.

Correspondence: Frank N. van Leeuwen, 412 Laboratory of Pediatric Oncology, Department of Pediatrics, Radboud University Medical Centre, PO

Box 9101, 6500 HB Nijmegen, The Netherlands; e-mail: frankn.vanleeuwen@radboudumc.nl.

References

1. Tong WH, Pieters R, Kaspers GJ, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. *Blood*. 2014;123(13):2026-2033.
2. Patel N, Krishnan S, Offman MN, et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. *J Clin Invest*. 2009;119(7):1964-1973.
3. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics*. 2010; 11:548.
4. Mach L, Stüwe K, Hagen A, Ballaun C, Glössl J. Proteolytic processing and glycosylation of cathepsin B. The role of the primary structure of the latent precursor and of the carbohydrate moiety for cell-type-specific molecular forms of the enzyme. *Biochem J*. 1992;282(pt 2):577-582.
5. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. *J Clin Oncol*. 1993; 11(9):1780-1786.
6. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. *Clin Pharmacokinet*. 2005;44(4):367-393.
7. Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. *Leukemia*. 2012; 26(11):2303-2309.
8. Sloane BF, Moin K, Krepela E, Rozhin J. Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. *Cancer Metastasis Rev*. 1990;9(4): 333-352.
9. Yan S, Sloane BF. Molecular regulation of human cathepsin B: implication in pathologies. *Biol Chem*. 2003;384(6):845-854.

© 2014 by The American Society of Hematology

To the editor:

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Based on the results of the PARMA and CORAL studies, high-dose chemotherapy (HDT) followed by autologous stem cell rescue has become the standard of care for patients with relapsed, chemosensitive aggressive non-Hodgkin lymphoma (NHL).^{1,2} Moreover, HDT/autologous stem cell rescue is considered the therapy of choice for Hodgkin lymphoma (HL) patients in chemosensitive relapse.³ However, HDT/autologous stem cell rescue is hampered by several major pitfalls, namely the toxicity related to the procedure and the lack of efficacy in chemoresistant patients.

We previously demonstrated the safety of a new HDT regimen with bendamustine, etoposide, cytarabine, and melphalan (BeEAM) prior to autologous stem cell rescue in 43 patients with resistant/relapsed lymphoma.⁴ The characteristics of patients are reported in the previously published paper.⁴ The study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice (ICH-GCP), and the current national guidelines for conducting clinical studies. The protocol was approved by the Institutional Ethics Committee. All subjects gave written informed consent. The study was registered at the European Medicines Agency with the European Clinical Trials Database number 2008-002736-15. Transplant-related mortality was 0%. The cumulative

incidence of infectious complications was approximately 60%, without any serious adverse events (grades 3-4). Furthermore, this regimen showed significant antilymphoma activity, with 80% of patients being in complete remission after transplant.⁵ Disease type (NHL vs HL) and disease status at transplant (chemosensitive vs chemoresistant) were the only statistically significant variables influencing progression-free survival (PFS), whereas disease status at transplant was the only variable affecting overall survival (OS) at the time of writing.⁴ However, the primary objective of the study was to determine the 36-month PFS rate, according to Fleming's method ([p0] = 40%, [p1] = 60%, $\alpha = 0.05$, and $1 - \beta = 0.80$). At the time of publication, the median follow-up for surviving patients was short (18 months), and therefore, it was not possible either to establish if we had met the primary end point of the study or to draw final conclusions on the efficacy of this regimen.

With this in mind, we updated the follow-up at 41 months after transplant in order to evaluate the midtime efficacy of the BeEAM regimen in terms of PFS and OS. Responses were again evaluated according to the criteria reported elsewhere by Cheson et al.⁵ At present, 31/43 patients are still in complete remission (72%), as documented by both PET and CT scans. Two patients (4.6%) were refractory to




Figure 1. Cumulative survival rates for Hodgkin and non-Hodgkin resistant/relapsed lymphoma patients treated with bendamustine, etoposide, cytarabine and melphalan followed by autologous stem cell rescue. (A) Progression-free and (B) overall survival of all patients.

the HDT regimen and rapidly died after HDT/autologous stem cell rescue, whereas 10/43 patients achieving at least a partial response (23%) relapsed after a median time of 7.5 months (range, 4-23 months) after HDT/autologous stem cell rescue. Five of those 10 patients died (3 NHL, 2 HL), and 5 patients are still alive after relapse.

Median PFS and OS were still not reached (Figure 1A-B). Conversely, 3-year PFS was 72%, allowing our study to meet its primary end point ($p[1]=60\%$). Interestingly, disease type (HL vs NHL) at transplant is no longer influencing PFS, and still does not influence OS. On the other hand, disease status at transplant (chemosensitive vs chemoresistant) is confirmed as a strong predictor of both PFS and OS ($P = .002$ and $P = .009$, respectively). However, the study was not designed to have the statistical power to compare disease entities, and therefore, the possible effect of HDT/autologous stem cell rescue regimen on disease type should be interpreted with caution, and needs additional confirmation in further trials. At present, 1 patient developed myelodysplasia after transplant. No other late effects were observed up to now.

Following the publication of the randomized CORAL study, whose results were less favorable than those reported in non-randomized studies,⁶ it has become critical to evaluate novel and effective HDT schedules in order to increase the number of clinical responses among relapsed/refractory lymphoma patients.⁷ In this regard, by meeting the primary end point of our BeEAM study, we showed that well-designed clinical trials incorporating new drugs in well-established HDT regimens may increase the number of lymphoma patients who become long-term survivors. This study provides the proof of principle for testing the BeEAM regimen in randomized phase 2-3 studies.

Giuseppe Visani

Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy

Pietro Maria Stefani

Hematology, Ca' Foncello Hospital, Treviso, Italy

Saveria Capria

Department of Biotechnologies and Hematology, Sapienza University, Rome, Italy

Lara Malerba

Hematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, Italy

Piero Galieni

Hematology, Ascoli Piceno, Italy

Francesco Gaudio

Division of Hematology, University of Bari Medical School, Bari, Italy

Giorgina Specchia

Division of Hematology, University of Bari Medical School, Bari, Italy

Giovanna Meloni

Department of Biotechnologies and Hematology, Sapienza University, Rome, Italy

Filippo Gherlinzoni

Hematology, Ca' Foncello Hospital, Treviso, Italy

Roberta Gonella

Hematology, San Martino Hospital, Genova, Italy

Marco Gobbi

Hematology, San Martino Hospital, Genova, Italy

Armando Santoro

Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy

Felicetto Ferrara

Division of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy

Marco Rocchi

*Institute of Biomathematics, Urbino University,
Urbino, Italy*

Enrique M. Ocio

*Department of Hematology, University Hospital and Cancer Research Center,
University of Salamanca,
Salamanca, Spain*

Maria Dolores Caballero

*Department of Hematology, University Hospital and Cancer Research Center,
University of Salamanca,
Salamanca, Spain*

Federica Loscocco

*Hematology and Stem Cell Transplant Center, Marche Nord Hospital,
Pesaro, Italy*

Alessandro Isidori

*Hematology and Stem Cell Transplant Center, Marche Nord Hospital,
Pesaro, Italy*

G.V. and A.I. contributed equally to this study.

Acknowledgments: The authors thank Mundipharma (Italy) for providing bendamustine free of charge. This study was supported in part by AIL Pesaro Onlus.

Contribution: G.V. and A.I. equally proposed, designed, and supervised the study and wrote the manuscript; L.M., P.M.S., S.C., P.G., F.G., G.S., G.M., F.G., R.G., M.G., A.S., and F.F. treated the patients, collected the data, and commented on the manuscript; M.R., F.L., and A.I. were responsible for statistical analysis; and E.M.O. and M.D.C. commented on the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Giuseppe Visani, Hematology and Hematopoietic Stem Cell Transplant Center, San Salvatore Hospital, Via Lombroso, 61100 Pesaro, Italy; e-mail: pesarohematology@yahoo.it.

References

- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol*. 2010;28(27):4184-4190.
- Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med*. 1995;333(23):1540-1545.
- Isidori A, Piccaluga PP, Loscocco F, et al. High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. *Expert Rev Hematol*. 2013;6(4):451-464.
- Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. *Blood*. 2011;118(12):3419-3425.
- Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. *J Clin Oncol*. 2007;25(5):579-586.
- Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. *Blood*. 2004;103(10):3684-3688.
- Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. *Biol Blood Marrow Transplant*. 2011;17(1):20-47, e30.

© 2014 by The American Society of Hematology

To the editor:

Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment

Endothelial cell protein C receptor (EPCR) plays a critical role in downregulating blood coagulation by promoting the activation of anticoagulant protein C by the thrombin:thrombomodulin (TM) complex.¹ Recent studies from our laboratory and others showed that prohemostatic clotting factor, factor VII (and factor VIIa [FVIIa]) also binds EPCR with the same affinity as that of protein C and activated protein C (APC).²⁻⁴ At present, the pathophysiological significance of the EPCR interaction with FVIIa in hemostasis is unclear. We postulated earlier that FVIIa binding to EPCR may augment the hemostatic effect of FVIIa in therapeutic conditions where high concentrations of FVIIa were used to restore hemostasis.^{2,5,6} In these conditions, FVIIa concentration in plasma may reach as high as that of plasma protein C, and therefore, effectively competes with protein C for limited EPCR on the endothelium. This would result in the downregulation of protein C/APC-mediated anticoagulant pathway, allowing FVIIa-induced thrombin generation without impediment. If this hypothesis is correct, then blockade of EPCR-mediated anticoagulant pathway by other means should also augment FVIIa's hemostatic effect in therapeutic conditions. Recently, Pavani et al⁷ showed that modified mouse FVIIa that binds EPCR exhibited superior hemostatic activity compared with wild-type mouse FVIIa and suggested that FVIIa tethering to EPCR on the endothelium may provide an extended locale of procoagulant reactions that is responsible for the procoagulant

effect of FVIIa. It is conceivable that both the downregulation of APC generation and EPCR-dependent FXa generation contribute to the hemostatic effect of FVIIa in therapeutic conditions.

To determine the potential mechanism of EPCR-dependent FVIIa's hemostatic effect in hemophilia, we investigated here the effect of mouse EPCR blocking (monoclonal antibody [mAb] 1560) and nonblocking antibodies (mAb 1567) on FVIIa-induced hemostasis in the hemophilia A mouse using the saphenous vein bleeding model.⁸ Both the blocking and nonblocking antibody bind to EPCR; the blocking antibody inhibits thrombin:TM-mediated protein C activation, whereas the nonblocking antibody does not.⁹ Neither antibody binds to mouse APC.⁹ The blocking antibody inhibits human FVIIa binding to mouse EPCR, whereas the nonblocking antibody does not.¹⁰ Saline or 3 different concentrations of human recombinant FVIIa were administered to hemophilia A mice via the tail vein 5 minutes before inducing saphenous vein injury. Following the injury, the time to hemostasis for each bleeding episode was recorded over a 30-minute time period, and the average time to achieve hemostasis (ATH) was calculated. Volume of blood loss was determined by measuring hemoglobin levels (see Figure 1 for details). Hemophilia A mice failed to achieve hemostasis within the 30-minute experimental time frame, whereas wild-type mice had an ATH of 64 seconds (Figure 1A). Administration of 1 mg/kg of FVIIa to hemophilia A mice had no